Reports Q4 revenue $99.01M, consensus $97.36M. “We ended the fiscal year with record revenue in the fourth quarter exceeding our guidance. By leveraging our technology, commercial execution and meeting the needs of our customers, we expanded our customer base and grew revenue 20% for the full fiscal year compared to the year prior,” said Emily Leproust, CEO and co-founder of Twist Bioscience (TWST). “As we enter fiscal 2026, we begin a new phase of growth for Twist, during which we expect to maintain gross margin above 50%, exit the fourth quarter of fiscal 2026 having achieved adjusted EBITDA breakeven and drive toward sustained and profitable growth.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Options Volatility and Implied Earnings Moves Today, November 14, 2025
- Cathie Wood Sells Tesla (TSLA) and SoFi Stocks, Makes a $34M Bet on This USDC Giant
- TWST Earnings this Week: How Will it Perform?
- Cathie Wood Sells Tesla (TSLA) Stock, and Buys This Stock after Q3 Beat
- Twist Bioscience initiated with an Overweight at Stephens